Immutep Ltd (NASDAQ: IMMP) is an Australian biotech developing LAG-3-based immunotherapies for cancer and autoimmune diseases. Its lead candidate, eftilagimod alpha, is in clinical trials for non-small cell lung cancer and breast cancer. As immuno-oncology continues to evolve, Immutep offers high-risk, high-reward exposure to checkpoint inhibitor innovation and global biopharma partnerships.
Derniers articles sur les actions